Seattle, WANCT05626920Now EnrollingIRB Ready

Inherited Retinal Dystrophy Primarily Involving Sensory Retina Clinical Trial in Seattle, WA

Access cutting-edge inherited retinal dystrophy primarily involving sensory retina treatment through this clinical trial at a research site in Seattle. Study-provided care at no cost to qualified participants.

Sponsored by University of Washington

Quick Self-Assessment

See if you qualify for this Seattle location

Preparing your pre-screening questions…

Expert Care in Seattle

Access inherited retinal dystrophy primarily involving sensory retina specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related inherited retinal dystrophy primarily involving sensory retina treatment provided free

Apply for This Seattle Location

Check if you qualify for this inherited retinal dystrophy primarily involving sensory retina clinical trial in Seattle, WA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Seattle

    Convenient for WA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Seattle site if eligible
  4. 4Begin participation

About This Inherited Retinal Dystrophy Primarily Involving Sensory Retina Study in Seattle

Aberrant retinoic acid signaling driven by the degenerating outer retina leads to pathological changes to the inner retina. The resulting hyperactivity of retinal ganglion cells leads to further diminution of the remaining vision in those afflicted with inherited retinal diseases. Inhibition of this pathway has led to improved visual function in murine models of retinal degeneration. This can be accomplished in humans with the FDA-approved irreversible inhibitor of aldehyde dehydrogenases, disulfiram.

Sponsor: University of Washington

Who Can Participate

Inclusion Criteria

Age ≥18 years Only those with a clinical diagnosis of inherited retinal degeneration. When available, supporting genetic diagnosis form a CLIA approved lab will be further considered for inclusion. Only one eye per subject should be identified as the study eye. The study eye must meet the following criteria:
Best corrected ETDRS visual acuity letter score ≥ 70 (i.e., 20/40 or better) within 30 days of enrollment.
Goldmann visual field exhibiting constriction of visual fields to 10 degrees centrally
Able and willing to provide informed consent
Willing and able to abstain from alcohol consumption for the duration of the study and the 2 weeks preceding it and 2 weeks following the study end point Liver function values that fall in the normal range as specified below:
Alanine transaminase (ALT): less than 40 IU/L
Aspartate transaminase (AST): less than 40 IU/L
Alkaline phosphatase (ALP): less than 300 IU/L
Albumin (Alb): less than 50 g/L
Total Protein: less than 80 g/L
Total Bilirubin: less than 30 umol/L

Exclusion Criteria

A condition that, in the opinion of the investigator, would preclude participation in the study, e.g., alcohol dependence, cardiovascular disease, hepatitis.
Individuals with a history of diabetes mellitus
Individuals with a history of psychosis
Individuals with hypothyroidism
Individuals with hypersensitivity to thiuram derivatives causing rubber contact dermatitis
Those on anticoagulant therapy or other medications that may be affected by disulfiram.
An ocular condition, other than inherited retinal degeneration, is present such that, in the opinion of the investigator, visual acuity might be affected (e.g., foveal atrophy, pigment abnormalities, dense subfoveal hard exudates, non-retinal conditions such as epiretinal membrane or vitreo-macular traction, vein occlusion, uveitis or other ocular inflammatory diseases such as neovascular glaucoma, etc).
History of major ocular surgery within the prior 6 months or major ocular surgery anticipated within the next 6 months following randomization.
Exam evidence of severe external ocular infection, including conjunctivitis, chalazion, or substantial blepharitis
Participation in an investigational trial that involves treatment with any drug within 30 days of randomization that has not received regulatory approval at the time of study entry. Note: study participants cannot receive another investigational drug while participating in this study.
Known allergy or hypersensitivity to any component of the study drug.
For women of child-bearing potential: pregnant or lactating or intending to become pregnant within the next 12 months. Women who are potential study participants should be questioned about the potential for pregnancy. Investigator judgment will be used to determine when a pregnancy test is needed.
Participants who expect to move out of the area of the clinical center during the 8 months of the study

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Seattle?

Yes, this clinical trial (NCT05626920) has an active research site in Seattle, WA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Inherited Retinal Dystrophy Primarily Involving Sensory Retina Treatment Options in Seattle, WA

If you're searching for inherited retinal dystrophy primarily involving sensory retina treatment options in Seattle, WA, this clinical trial (NCT05626920) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Seattle research site is actively enrolling participants for this clinical trial. You'll receive care from experienced inherited retinal dystrophy primarily involving sensory retina specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all inherited retinal dystrophy primarily involving sensory retina clinical trials near you to find additional studies recruiting in your area.

More Essential Tremor Trials in Seattle, WA

See all essential tremor clinical trials recruiting in Seattle — not just this study.

Browse Essential Tremor Trials in Seattle →

Browse More Trials by Condition

Essential Tremor TrialsPulmonary Hypertension TrialsErectile Dysfunction TrialsRetinitis Pigmentosa TrialsAll Conditions →

Ready to Join in Seattle?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Seattle, WA